A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

por Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Publicado 2007

The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escal...

por Molife, L R, Fong, P C, Paccagnella, L, Reid, A H M, Shaw, H M, Vidal, L, Arkenau, H-T, Karavasilis, V, Yap, T A, Olmos, D, Spicer, J, Postel-Vinay, S, Yin, D, Lipton, A, Demers, L, Leitzel, K, Gualberto, A, de Bono, J S
Publicado 2010

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

por Yap, T A, Cortes-Funes, H, Shaw, H, Rodriguez, R, Olmos, D, Lal, R, Fong, P C, Tan, D S, Harris, D, Capdevila, J, Coronado, C, Alfaro, V, Soto-Matos, A, Fernández-Teruel, C, Siguero, M, Tabernero, J M, Paz-Ares, L, de Bono, J S, López-Martin, J A
Publicado 2012